$伊希斯医药品(ISIS)$ June 11 (Reuters) - Isis Pharmaceuticals Inc (ISIS.O) :

* Isis Pharmaceuticals reports data from ISIS-SMN Rx phase 2 study in infants with spinal muscular atrophy

* Says safety and tolerability profile of Isis-smnrxto date continues to support further development

* Data show increases in median event-free survival and muscle function scores as well as achievement of developmental milestones

* Currently collaborating with Biogen to develop and potentially commercialize Isis-smnrxto treat patients with sma

* Source text for Eikon

* Further company coverage (ISIS.O)

网页链接